Recurrence pattern analysis after re-irradiation with bevacizumab in recurrent malignant glioma patients by unknown
Niyazi et al. Radiation Oncology  (2014) 9:299 
DOI 10.1186/s13014-014-0299-yRESEARCH Open AccessRecurrence pattern analysis after re-irradiation
with bevacizumab in recurrent malignant glioma
patients
Maximilian Niyazi1*, Nathalie Lisa Jansen2, Maya Rottler1, Ute Ganswindt1 and Claus Belka1Abstract
Background: The aim of the present analysis was to evaluate the recurrence pattern in patients with recurrent
malignant glioma after re-irradiation in combination with bevacizumab as there is limited data on how to optimally
choose dose, fractionation and delineation margins.
Methods: Thirty-one patients with recurrent malignant glioma treated with re-irradiation and bevacizumab after
previous chemoradiotherapy (concurrent temozolomide 75 mg/m2/d according to the EORTC/NCIC trial) and
[18 F]FET-PET and/or MRI confirmed recurrence were retrospectively analyzed. Bevacizumab was applied twice
during fractionated re-irradiation (10 mg/kg, d1 + d15, median 36 Gy, conventionally fractionated). Recurrence
patterns were assessed by means of [18 F]FET-PET and/or MRI.
Results: Median follow-up was 34.0 months for all patients [95%-CI, 27.7-40.3] and median post-recurrence survival
10.8 months [95%-CI, 9.2-12.4]. Concerning the recurrence patterns, 61.3% of these were located in-field (19 patients),
22.6% were marginal (7 patients) and 16.1% ex-field (5 patients). No influence on the recurrence pattern was observed
according to sex, WHO grade, maintenance chemotherapy or MGMT methylation status whereas planning target
volume (PTV) size had a significant influence on the recurrence pattern (p = 0.032). PTV sizes > 75 ml were
associated with a higher in-field recurrence rate and lower median post-recurrence progression-free survival
(8.5 vs. 4.9 months, p = 0.016).
Conclusions: After the administration of re-irradiation with bevacizumab the recurrence pattern seems to be
mainly centrally located. The PTV size was the main predictor for a marginal/ex-field recurrence.
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In patients with high-grade glioma (HGG) a high rate of
local failures has been observed after multimodal therapy
[1]. The addition of temozolomide (TMZ) increased local
control and survival whereas the 2-year survival rate
remained 27.2% [2].
In selected patients, a second course of radiotherapy
(RT) might be a reasonable treatment option despite the
relative lack of prospective randomized data [3-6]. Con-
trarily, conventional cytotoxic approaches were found to
be not adequately effective [7-10] so molecularly targeted* Correspondence: maximilian.niyazi@med.uni-muenchen.de
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are currently undergoing clinical testing.
Various groups have investigated the use of bevacizumab –
a humanised monoclonal antibody against VEGF-A with
an already established role in metastatic colon, breast, and
lung cancer [11] – for patients with recurrent HGG [12]
and several trials have documented its efficacy [13-17]
which may be due to the presence of pronounced hypoxia
as well as high levels of tumor driven angiogenesis in
HGG [18].
Since the efficacy of radiation-based re-treatment is lim-
ited, it is reasonable to test how far the addition of a puta-
tive radiation response modulator would impact on the
efficacy of re-treatment. In this regard, one group tested
the sequential use of radiosurgery and bevacizumab withThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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determined the safety and efficacy of radiotherapy (RT)
and concomitant bevacizumab – for the GBM cohort,
progression-free survival at six months (PFS-6) was
65% [20]. In a previous retrospective study on 30 recur-
rent malignant glioma patients undergoing re-irradiation,
20 treated with bevacizumab and 10 without bevacizumab
we showed that PFS-6 within the bevacizumab-treated
cohort was 72% and survival was significantly enhanced
[21]. With substantially longer follow-up and a higher pa-
tient number, the significant post-recurrence survival
(PRS) benefit of bevacizumab could be confirmed within a
second study describing a beneficial treatment with a low
rate of side-effects [22]. Recent prospective phase III trials
(AVAglio & RTOG 0825) were designed to prove the effi-
cacy of TMZ based radio-chemotherapy with bevacizumab
as first-line therapy but failed to show a survival benefit
whereas significant and marginally significant progression-
free survival benefits have been observed [23,24].
In our study we retrospectively analyzed the pattern of
re-recurrence in recurrent HGG patients undergoing re-
irradiation with bevacizumab as there is limited data on
how to choose proper safety margins during radiotherapy
planning and furthermore, in how far the chosen fraction-
ation schedule yielded adequate local control rates.Material and Methods
Patient selection
Only patients with histologically and/or [18 F]FET-PET/
MRI proven recurrence of high-grade gliomas (WHO
grades III + IV) and macroscopic tumor (maximum
diameter 6 cm, multifocality per se was not a contraindi-
cation) underwent re-irradiation, the interval between
first radiotherapy and re-irradiation had to be 6 months
at minimum. Another precondition was the absence of
meaningful alternative treatment options, e. g. complete
resection by re-surgery, interstitial brachytherapy or sys-
temic chemotherapy.Treatment schedule and follow-up
Before treatment, a gadolinium-enhanced brain MRI with
gradient echo sequence and perfusion and/or a [18 F]FET-
PET. Patients treated with bevacizumab received 10 mg/
kg at days 1 and 15 during re-irradiation. If TMZ was ap-
plied concomitantly in patients who had no previous pro-
gression after TMZ pre-treatment a dosage of 75 mg/m2
daily was chosen.
Treatment outcome was evaluated on a regular basis
(every three months) by brain MRI as described by [25]
and/or [18 F]FET-PET.
Adjuvant chemotherapy was prescribed on an individ-
ual basis as no standard has been defined yet but was
not defined as mandatory.[18 F]FET-PET data acquisition and analysis
Dynamic PET scans were acquired on a Siemens ECAT
EXACT HR+ scanner (Siemens/CTI, Knoxville, TN, USA)
after intravenous injection of approximately 180 MBq
[18 F]FET according to a standardized protocol [26]. Data
were reconstructed by filtered back projection using a
Hann filter, corrected for scatter and attenuation and
afterwards transferred to a HERMES workstation (Hermes
Medical Solutions, Sweden) for further data processing.
PET-based evaluation of recurrence was performed by
an experienced nuclear physician by assessment of the
maximal standardized uptake value within the tumour
corrected for the unspecific uptake in the background
(SUVmax/BG > 1.6) in combination with a previously in-
troduced dynamic analysis of [18 F]FET kinetic uptake
behaviour [27]. Furthermore, the biological tumor vol-
ume was assessed, which was defined by semi-automatic
threshold-based calculation of a volume of interest.
Radiotherapy
By analogy with Combs et al. [28] patients received a total
dose of 36 Gy in 18 fractions (2 Gy single doses) employing
3D conformal radiotherapy or intensity-modulated radio-
therapy (IMRT) if adjacent critical structures were present.
Planning target volume (PTV) was defined as gross tumor
volume (GTV) plus 10 mm margin at maximum. GTV in-
cluded the contrast enhancing lesion in T1w +Gd MRI.
To ensure reproducibility patients were immobilized with
a thermoplastic mask system. Treatment planning was per-
formed using the Oncentra® treatment planning system
(OTP MasterPlan®, Elekta, Crawley, UK).
Analysis of recurrence pattern
Recurrences were defined as “in-field” if more than 80%
of the tumour recurrence resided within the prescription
95% isodose surface, and “marginal” if 20% to 80% of the
lesion was inside the 95% isodose surface. In all other
cases, recurrences were defined as outside the radiation
field (“ex-field”) according to the study of Lee et al. [29];
in case of a multifocal recurrence, the part lying most
distant to the initial tumour site was taken as reference.
Statistics
Tumour progression was defined according RANO cri-
teria [30] or by the appearance of new vital/progressive
tumour lesions by means of dynamic [18 F]FET-PET. Post-
recurrence progression-free (PR-PFS) and post-recurrence
survival (PRS), measured from the beginning of re-
irradiation to progression or death, respectively, or date of
last follow-up, were analyzed using the Kaplan-Meier
method; 95% CIs were calculated using the associated esti-
mated standard errors. The log-rank test was used to test
the significance of the following prognostic variables:
MGMT promoter methylation status, age, surgery and
Table 1 Patient characteristics, N = 31
Characteristic Patients
Sex
• Male 21 (67.7%)
• Female 10 (32.3%)
Median Age [y] 51.0 (18 – 67)
Median KPS 80 (40 – 100)
• KPS < 70 8 (25.8%)
• KPS ≥ 70 23 (74.2%)
Median dose of primary radiotherapy 60 Gy
Median dose of re-irradiation 36 Gy
Median PTV size [ml] 118.1 (34.3 – 363.9)
MGMT methylation status
• methylated 11 (35.5%)
• not methylated 18 (58.1%)
• unknown 2 (6.5%)
WHO grade at relapse
• III 6 (19.4%)
• IV 25 (80.6%)
Recurrence pattern
• in-field 19 (61.3%)
• marginal 7 (22.6%)
• distant 5 (16.1%)
Imaging type for recurrence
• MRI/CT 10 (32.3%)
• PET 21 (67.7%)
Table 2 Logistic regression analysis on recurrence pattern
(in-field vs. marginal/distant), N = 31, ns – not significant,
meth – MGMT methylated, HR – hazard ratio
Variable Univariate p-value HR
Age (<60 y, ≥ 60 y) ns (p = 0.423) 1.875
MGMT (meth/not meth) ns (p = 0.361) 2.00
PTV size p = 0.032 0.986
WHO grade at relapse (III/IV) ns (p = 0.165) 0.200
Sex (male/female) ns (p = 0.914) 0. 923
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patients with recurrence at RT margin were grouped with
patients having an ex-field recurrence in the analysis of time
to progression. A logistic regression analysis was performed
to determine variables with significant influence on the re-
currence pattern. Proportions were compared using Fisher’s
exact test. A p-value ≤ 0.05 was considered significant.
The scientific use of retrospective data has been expli-
citly allowed by Bavarian federal law. Additionally, all
patients agreed that their scientific data could be used.
No experimental research on humans or animals has
been performed or reported. The declaration of Helsinki
has been obeyed in all points.
Results
Thirty-one patients with recurrent HGG were included into
this retrospective analysis and treated at the Department
of Radiation Oncology, University Hospital of Munich
from 8/2008 until 7/2012, median age was 51 years (range,
18 – 67 years) and 74.2% of the patients were younger
than 60 years.
Median radiotherapy dose was 36 Gy in 2 Gy single
fractions and two applications of bevacizumab had been
applied concomitantly.
MGMT methylation status was not available in 2 cases
(6.5%), 11 of the remaining 29 patients were MGMTmeth-
ylated (35.5%), for other patient characteristics see Table 1.
Median follow-up was 34.0 months for all patients
[95%-CI, 27.7 - 40.3], median post-recurrence survival was
10.8 months [95%-CI, 9.2 - 12.4].
Concerning the recurrence patterns of the 31 patients,
61.3% of these were located in-field (19 patients), 22.6%
were marginal (7 patients) and 16.1% ex-field (5 patients).
In view of the small numbers, we summarized both
patients with marginal and ex-field recurrences as these
were patients where a 10 mm PTV margin was probably
too narrow (38.7%). Thus, marginal and ex-field recur-
rences were grouped and subsequent analyses were
based on this precondition.
Concerning PRS and PR-PFS, no significant univariate
factors could be obtained with an influence on latter
endpoints including KPS, sex, age, WHO grade at re-
lapse, MGMT methylation status, PTV size (continuous
variable) or recurrence patterns.
Therefore, we further analyzed which factors would in-
fluence the pattern of recurrence.
Univariate testing was performed employing the same
factors without the KPS - all could be identified to be
non-significant except the PTV size with a hazard ratio
of 0.986 (p = 0.032), see Table 2.
We performed an ROC analysis to determine the optimal
threshold of the PTV to stratify between in-field and mar-
ginal/ex-field recurrences and determined 75 ml as optimal
size (which is equal to the 25th quartile of all PTV sizes).Fisher’s exact test showed a trend for a correlation be-
tween recurrence pattern and PTV size (as binary variable
with 75 ml as threshold); 5 recurrences were marginal/ex-
field compared to 2 in-field recurrences for PTV sizes
smaller than 75 ml whereas larger PTV sizes were associ-
ated with a high in-field recurrence rate, 17 in-field vs. 7
ex-field recurrences (p = 0.078). This constructed binary
variable showed a trend in predicting the type of recur-
rence (hazard ratio 0.17, p = 0.058).
Finally, we compared the PFS rates in both PTV size
groups and obtained a significant difference (8.5 vs.
4.9 months, p = 0.016) which is shown in Figure 1. PRS
Figure 1 PR-PFS for patients with PTV size > 75 ml or ≤ 75 ml.
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10.1 months, p = 0.276).
Discussion
For certain subgroups of recurrent high-grade glioma pa-
tients re-irradiation may be a strategy to prolong survival
with acceptable toxicity. The aim of this study was to
analyze the re-recurrence pattern after re-irradiation keep-
ing in mind that this is the largest cohort to our knowledge
uniformly treated with re-irradiation and bevacizumab in
one center.
A mainstay in treatment follow-up is a reliable im-
aging modality: Whereas conventional magnetic-resonance-
imaging (MRI) provides information on the size and
localization of the tumor and delineates secondary phe-
nomena such as haemorrhage, oedema, and mass effect,
positron emission tomography (PET) with diverse radi-
olabelled compounds has been proposed to characterize
the tumour on a metabolic and molecular level [31].
In particular, different radiolabelled amino acids like
[11C]Methionine ([11C]MET) [32] as well as aromatic
amino acid analogues like [18 F]Fluoroethyltyrosine
([18 F]FET) [33] were previously proposed to provide valu-
able additional information in patients with glioma [34,35].
MRI was regularly performed as follow-up imaging -
[18 F]FET-PET imaging was routinely performed (67.7%)
or in case of a questionable progression (according to
MRI), as it was proposed to reliably distinguish between
post-therapeutic benign lesions and tumour recurrence
after treatment of low- and high-grade gliomas [36,37].
To our knowledge, the only group having also deter-
mined the recurrence pattern after re-irradiation withbevacizumab were Shapiro et al. [38] who derived 50%
central recurrences. Their treatment strategy was built
on a very tight margin with 5 mm to the contrast-
enhancing lesion including 5 fractions with 6 Gy single
doses, two fractions per week.
From our observation, 2/36 Gy is locally active in com-
bination with bevacizumab, but recurrences mainly seem to
be central which leaves us to speculate that a dose escal-
ation could be warranted - especially due to the radiopro-
tective potential of bevacizumab [39]. Other groups have
tested 36 Gy in 2 Gy single fractions with adequate to very
moderate activity, recent and several ongoing studies in-
clude rather higher single doses (2.4 Gy, 3 Gy, 3.5 Gy).
For smaller lesions, marginal and ex-field recurrences
are more often observed which could generate the hy-
pothesis that larger lesions display an increased radiore-
sistant behavior, potentially due to hypoxic conditions
and a larger number of tumor stem cells. These findings
might lead to an adaption of planning margins according
to the size of the lesion, e. g. with a central simultaneous
boost technique in large tumor volumes which might be
justified by the altogether dismal prognosis of this pa-
tient group. As target delineation is mainly based on
contrast-enhanced MRI, the relatively higher rate of ex-
field recurrences in smaller lesions could be explained
by a tumor miss due to small margins (whereas 10 mm
are at the higher end of the literature).
The discussion about the tumor size itself as prognostic
parameter has not been resolved - despite its relevance
on the recurrence pattern, there was no significant in-
fluence on survival - even the prognostic score defined by
Combs et al. did not include the size itself as parameter
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to now [40-42].
Other recurrence analyses in the primary setting have
determined a relation with molecular genetics [1,43]
which could not be confirmed in the recurrence setting.
Furthermore, no increase in distant failures could be ob-
served such as in smaller series of primary glioblastoma
patients after concurrent radiotherapy, bevacizumab and
temozolomide [44]. Conversely, the low rate of in-field
recurrences was not reproducible due to dose limitations
during re-irradiation.
All in all, after the administration of re-irradiation
with bevacizumab recurrences seem to be mainly cen-
trally located. The PTV size was the main predictor for a
marginal/ex-field recurrence. It would be valuable to have
future studies evaluating the role of dose escalation to the
central part of the tumor, e. g. as a stereotactic dose escal-
ation or by means of a simultaneous integrated boost
(SIB) as shown for many other sites [45-47].
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